Last Update Time:
19-Mar-2025 12:27:50
ISIN:
INE634S01028
Sector:
Healthcare
Symbol:
MANKIND
Mankind Pharma Limited
₹2,162.50
₹16.70
(0.78%)
▲
Prev. Close
₹2,145.80
Open
₹2,170.00
Close
₹0.00
Range
₹2,054.38 - ₹2,270.63
High
₹2,181.40
Low
₹2,132.00
Ind. Close
₹0.00
VWAP
₹2,159.32
The current stock price of Mankind Pharma Limited is ₹2,162.50, with a target price range between ₹2,054.38 and ₹2,270.63. The stock has experienced a price change of ₹16.70 (0.78%), reflecting recent market volatility.
Today's opening price was ₹2,170.00, while the previous close stood at ₹2,145.80.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Mankind Pharma Limited Price Chart
Mankind Pharma Limited Pre Open Market Overview: 19-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 2170
- Previous Close Price: 2145.8
- Change: 24.20%
- Total Traded Volume: 333
- Total Buy Quantity: 9,426
- Total Sell Quantity: 7,332
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 2,151.00 | 1.00 | 0.00 |
| 2,152.90 | 175.00 | 0.00 |
| 2,153.00 | 101.00 | 0.00 |
| 2,155.00 | 625.00 | 0.00 |
| 2,170.00 | 35.00 | 0.00 |
| 2,173.00 | 0.00 | 100.00 |
| 2,173.65 | 0.00 | 4.00 |
| 2,174.00 | 0.00 | 11.00 |
| 2,175.00 | 0.00 | 315.00 |
| 2,175.95 | 0.00 | 10.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 2,161.10 | 2 | 2,162.50 | 3 |
| 2,161.05 | 10 | 2,162.55 | 4 |
| 2,160.90 | 2 | 2,162.65 | 5 |
| 2,160.70 | 2 | 2,162.70 | 17 |
| 2,160.50 | 11 | 2,162.75 | 9 |
Total Buy Quantity: 9426
Total Sell Quantity: 7332
Shareholding Patterns of Mankind Pharma Limited
Key Trade Statistics of Mankind Pharma Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 6.53 |
| Traded Value (₹ Cr.) | 140.95 |
| Total Market Cap (₹ Cr.) | 89,220.11 |
| Free Float Market Cap (₹ Cr.) | 22,408.70 |
| Impact cost | 0.05 |
| Quantity Traded | 631,913.00 |
| Deliverable Quantity | 485,507.00 |
| % of Quantity to Traded | 76.83 |
| Security VaR | 12.72 |
| Index VaR | N/A |
| VaR Margin | 12.72 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 16.22 |
| Face Value | 1 |
Key Price Statistics of Mankind Pharma Limited
The 52-week high for Mankind Pharma Limited was ₹3,054.80, recorded on 23-Dec-2024. On the other hand, the 52-week low stands at ₹1,901.05, with the lowest value recorded on 05-Aug-2024.
The upper band for trading is ₹2,574.95, and the lower band is ₹1,716.65. The price band is 20%.
The stock's daily volatility stands at 2.00, while the annualized volatility is 38.21. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (23-Dec-2024) | 3,054.80 |
| 52 Week Low (05-Aug-2024) | 1,901.05 |
| Upper Band | 2,574.95 |
| Lower Band | 1,716.65 |
| Price Band (%) | 20 |
| Daily Volatility | 2.00 |
| Annualised Volatility | 38.21 |
| Tick Size | 0.05 |
Key Securities Statistics of Mankind Pharma Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 09-May-2023 |
| Adjusted P/E | 43.17 |
| Symbol P/E | 43.17 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Mankind Pharma Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Mankind Pharma Limited
| Subject | Date |
|---|---|
| General Updates | 01-Mar-2025 |
| General Updates | 28-Feb-2025 |
| Update-Acquisition/Scheme/Sale/Disposal-XBRL | 27-Feb-2025 |
| General Updates | 27-Feb-2025 |
| Credit Rating | 25-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 20-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 20-Feb-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 18-Feb-2025 |
Corporate Actions of Mankind Pharma Limited
| Face Value | Purpose | Ex-Date | ||
|---|---|---|---|---|
| No corporate actions available | ||||
Board Meetings of Mankind Pharma Limited
Financial Results of Mankind Pharma Limited
Company Directory of Mankind Pharma Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| N/A | Head Office/ Corporate Office | 262, Okhla Industrial Estate Phase - III | NEW DELHI |
| N/A | Registered Office | 208, Okhla Industrial Estate Phase - III | NEW DELHI |
| N/A | Transfer Agent | Selenium, Tower B, Plot No. 31 and 32 Financial District, Nanakramguda, Serilingampally Hyderabad Rangareddi | HYDERABAD |
Insider Trading of Mankind Pharma Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Sheetal Arora | 3829202464 | Sell |
| 7(2) | Arjun Juneja | 5060017091 | Sell |
| 7(2) | Puja Juneja | 4786499920 | Sell |
Annual Reports of Mankind Pharma Limited
Investor Complaints of Mankind Pharma Limited
Event Calendar of Mankind Pharma Limited
| Purpose | Details |
|---|---|
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Financial Results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday, 2nd August 2023, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on 30th June 2023. |
| Financial Results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company will be held on Tuesday, October 31, 2023, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2023.Further, in continuation of our earlier letter dated September 27, 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till November 02, 2023.The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. |
| Financial Results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday, January 31, 2024, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended on December 31, 2023.Further, in continuation of our earlier letter dated December 27, 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till February 02, 2024.The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. |
| Financial Results/Fund Raising | To consider and approve the financial results for the period ended March 31, 2024 and to evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
| Financial Results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of Board of Directors of the Company will be held on Wednesday, July 31, 2024, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30, 2024. |
| Fund Raising | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, we wish to inform you that a meeting of Board of Directors of the Companywill be held on September 20, 2024, inter-alia to consider and approve the raising of funds byway of issue of non-convertible debentures, commercial papers, other debt securities or any othersecurity or any combination thereof for an amount as may be decided by the Board. |
| Financial Results | To consider and approve the unaudited financial results for the quarter and half year ended on September 30, 2024 |
| Financial Results | To consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2024 |
| Financial Results | To consider and approve the unaudited financial results for the quarter and nine months ended on December 31, 2024 |
Share Transfers of Mankind Pharma Limited
Voting Results of Mankind Pharma Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 21-DEC-2024 | Postal Ballot | Approval for amendment in articles of association |
| 21-DEC-2024 | Postal Ballot | Approval for creation of pledge on the equity Shares of Bharat Serums And Vaccines Limited, Material wholly owned subsidiary of the Company |
| 21-DEC-2024 | Postal Ballot | Approval for creation of mortgage and/or Charge on all or any of the tangible and/or Intangible assets of the company |
| 09-AUG-2024 | AGM | To receive consider and adopt a. The Standalone Audited Financial Statements for the financial year ended March 31, 2024 and the Reports of the Board of Directors and Auditors thereonnb. The Consolidated Audited Financial Statements for the financial year ended March 31, 2024 and the Reports of the Auditors thereonn |
| 09-AUG-2024 | AGM | Ratification of the remuneration of cost auditor for the Financial Year 2024-25 |
| 09-AUG-2024 | AGM | Re-appointment of M/s. S. R. Batliboi & Co. LLP, Chartered Accountants as joint statutory auditors of the Company |
| 09-AUG-2024 | AGM | To appoint a Director in place of Mr. Satish Kumar Sharma (DIN: 07615602), who retires by rotation and being eligible, offers himself for re-appointment. |
| 17-JUN-2024 | Postal Ballot | Approval for increase in the authorised share capital and consequent amendment to the Memorandum of Association |
| 17-JUN-2024 | Postal Ballot | Approval for creation of mortgage and/or charge on all or any of the movable and/or immovable properties of the Company |
| 17-JUN-2024 | Postal Ballot | Approval for increase the borrowing limit under Section 180(1)(c) of the Companies Act, 2013 |
| 17-JUN-2024 | Postal Ballot | Approval for enhancement of limit for the loan, guarantee and investment by the company under Section 186 of the Companies Act, 2013 |
| 17-JUN-2024 | Postal Ballot | Approval for raising of funds in one or more tranches through issuance of equity shares and/or other securities to eligible investors |
| 22-SEP-2023 | AGM | 1. To receive, consider and adopt: -na. The Standalone Audited Financial Statements for the financial year ended March 31, 2023 and the Reports of the Board of Directors and Auditors thereon.nb. The Consolidated Audited Financial Statements for the financial year ended March 31, 2023 and the Reports of the Auditors thereon. |
| 22-SEP-2023 | AGM | TO APPOINT A DIRECTOR IN PLACE OF MR. RAJEEV JUNEJA (DIN: 00283481), WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT. |
| 22-SEP-2023 | AGM | RE-APPOINTMENT OF MR. RAMESH JUNEJA (DIN: 00283399) AS CHAIRMAN AND WHOLE-TIME DIRECTOR OF THE COMPANY |
| 22-SEP-2023 | AGM | RE-APPOINTMENT OF MR. RAJEEV JUNEJA (DIN: 00283481) AS VICE CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY |
| 22-SEP-2023 | AGM | RE-APPOINTMENT OF MR. SHEETAL ARORA (DIN: 00704292) AS CHIEF EXECUTIVE OFFICER AND WHOLE-TIME DIRECTOR OF THE COMPANY |
| 22-SEP-2023 | AGM | RATIFICATION OF THE ￂMANKIND EMPLOYEE STOCK OPTION PLAN 2022ￂ (ￂESOP 2022ￂ/ ￂPLANￂ) |
| 22-SEP-2023 | AGM | RATIFICATION OF GRANT OF EMPLOYEE STOCK OPTIONS TO THE EMPLOYEES OF GROUP COMPANY(IES) INCLUDING SUBSIDIARY COMPANY(IES) OR ASSOCIATE COMPANY(IES) UNDER ￂMANKIND EMPLOYEE STOCK OPTION PLAN 2022ￂ |
| 22-SEP-2023 | AGM | RATIFICATION OF THE REMUNERATION OF COST AUDITOR FOR THE FINANCIAL YEAR 2023-24 |
FAQs on Mankind Pharma Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.